Latest News

Vulcan Energy Resources (ASX:VUL) has just locked in a €2.2 billion financing package to fully fund Phase One of its Lionheart lithium and renewable energy project in Germany, pushing the business firmly into execution mode. See our latest analysis for Vulcan Energy Resources. The hefty equity raise at a discount has clearly weighed on sentiment, with a 30 day share price return of minus 30.55 percent and 1 year total shareholder return of minus 25.27 percent. However, the positive 90 day...

Xeris Biopharma Holdings recently received a Notice of Allowance from the USPTO for a patent application covering XP-8121, its investigational once-weekly levothyroxine formulation, and earlier this month presented at the Piper Sandler 37th Annual Healthcare Conference in New York. The XP-8121 formulation patent progress strengthens Xeris’s intellectual property position in levothyroxine delivery, potentially reinforcing its efforts to address well-known limitations of oral thyroid hormone...

Grocery Outlet Holding (GO) has quietly slipped into value territory after a steep slide over the past 3 months, even as revenue and net income growth trends tell a more mixed and nuanced story. See our latest analysis for Grocery Outlet Holding. Over the past year, that weakness has added up, with a roughly 30 percent year to date share price decline and a 1 year total shareholder return of about negative 40 percent, suggesting sentiment has shifted from growth story to turnaround watch. If...

Halozyme Therapeutics (HALO) just caught investors attention after a Zacks upgrade to Rank #2, Buy, driven by rising earnings estimates and upbeat reactions to its latest quarter and guidance. See our latest analysis for Halozyme Therapeutics. Despite a choppy stretch, including a 7‑day share price return of minus 13.36 percent and some insider selling, Halozyme still has a year‑to‑date share price return of 31.12 percent and a 1‑year total shareholder return of 30.98 percent. This suggests...

On 4 December 2025, Veritone and Armada announced a partnership to deliver a fully integrated edge-to-enterprise data fabric that ingests, analyzes, and monetizes high-volume audio, video, drone, and sensor streams in real time for public agencies and commercial content owners. A distinctive element of this deal is its focus on turning real-world media and sensor feeds into AI-ready digital tokens, reinforcing Veritone’s push to treat data as a renewable, monetizable asset class. We’ll now...

Wondering if United Natural Foods is still a bargain after its big run over the years, or if you have missed the boat? This breakdown will help you decide whether UNFI deserves a spot on your watchlist right now. Despite a recent pullback, with the stock down 8.6% over the last week and 7.6% over the last month, United Natural Foods is still up 23.6% year to date and 41.7% over the past year. This hints that sentiment has shifted meaningfully. Investors have been reacting to ongoing efforts...

Beam Therapeutics (BEAM) jumped after analysts upgraded their outlook, pointing to progress in its sickle cell disease program and smoother manufacturing, a combination that has quickly boosted market confidence in the gene editing specialist. See our latest analysis for Beam Therapeutics. The upbeat call from analysts lands on top of already strong momentum, with an 8.12% 1 day share price return feeding into a 38.46% 90 day share price return, even as the 3 year total shareholder return...

Tower Semiconductor (NasdaqGS:TSEM) is back on traders’ radar after Q3 revenue ticked higher sequentially, and management doubled down with a fresh $300 million push into RF infrastructure and silicon photonics capacity. See our latest analysis for Tower Semiconductor. The latest capacity push comes on top of a powerful rerating, with a 30 day share price return of 32.17 percent and an 82.04 percent 90 day share price return feeding into a 130.97 percent 1 year total shareholder return. This...

Lincoln Financial recently announced that Nilanjan (Neel) Adhya will become Executive Vice President and Chief AI, Data and Analytics Officer in January 2026, reporting directly to CEO Ellen Cooper and joining the Senior Management Committee. By recruiting a veteran of BlackRock and IBM to build AI and data into core capabilities, Lincoln is signaling a deeper push to modernize customer experience and operations across its insurance and retirement businesses. We’ll now explore how appointing...

Roblox (RBLX) just put its new advertising unit front and center, rolling out Rewarded Video ads that some on Wall Street think could reshape how the platform makes money over the next few years. See our latest analysis for Roblox. The new ad push lands as Roblox’s 1 year to date share price return of 61.81 percent and 1 year total shareholder return of 61.54 percent signal strong, but recently choppy, momentum around a 95.21 dollar share price. If this kind of ad driven growth story...

Thomson Reuters (TSX:TRI) is back in focus after unveiling a multi year Frontier AI research lab with Imperial College London, alongside a new Value Alignment Strategic Toolkit for in house legal teams navigating rapid technological change. See our latest analysis for Thomson Reuters. Those AI and legal tech moves arrive after a tough stretch for the stock, with a roughly 22.9 percent 3 month share price return decline. At the same time, a still solid 5 year total shareholder return near...

PPL (PPL) has quietly slipped about 7% over the past week and 6% over the past month, even though its year to date return is still positive. This invites a closer look at what has changed. See our latest analysis for PPL. Even with this recent pullback in the share price, which leaves the latest close at $34.16, PPL still boasts a solid multi year total shareholder return. This suggests the market is reassessing near term risk rather than abandoning the longer term story. If PPL’s move has...

Science Applications International (SAIC) opened Q3 2026 with Q2 revenue of about $1.8 billion and basic EPS of $2.72, setting the tone for another data heavy earnings season. The company has seen quarterly revenue move from $1.82 billion in Q2 2025 to $1.77 billion in Q2 2026, while EPS over that same span ranged from $1.59 to $2.72. This frames a period of shifting top line and per share results that investors will be watching closely. With trailing net profit margins now higher than a year...

Wondering if Universal Display at around $121 still has the makings of a long term winner, or if the market has already priced in the upside? This breakdown will help you decide whether the current tag looks like opportunity or risk. The stock has bounced 2.1% over the last week but is still down 17.2% over the past month, 18.8% year to date and 22.3% over the past year. This is a volatile pattern that hints at shifting market sentiment rather than a clear long term trend. Recent headlines...

If you have been wondering whether American Tower is quietly turning into a value opportunity or a value trap, you are not alone. This article is going to unpack exactly that. Despite its scale and critical role in wireless infrastructure, the stock is down about 11.6% over the last year and roughly flat to slightly negative over the last few months. This has many investors asking if the current price finally compensates for the risks. Recent moves in interest rates and shifting expectations...

If you are wondering whether Regeneron Pharmaceuticals is a smart buy at its current price, you are in the right place to dig into what the market might be missing. The stock has been volatile lately, slipping 7.9% over the last week but still up 15.1% over the past month and 51.7% across five years, which hints at shifting sentiment rather than a simple up or down story. Recent headlines have focused on Regeneron’s expanding pipeline and regulatory milestones, from new trial readouts in eye...

Gen Digital (GEN) has been quietly grinding higher this month, even as its past 3 months performance remains in the red. That gap between recent momentum and longer term returns is what catches my eye. See our latest analysis for Gen Digital. At around a 4.7% 1 month share price return, but still a slightly negative year to date move, Gen Digital’s near term momentum looks to be rebuilding even though the 1 year total shareholder return remains in the red. If you are watching Gen Digital’s...

Omega Healthcare Investors (OHI) just caught a fresh wave of analyst attention after beating third quarter earnings expectations, and that combination of upbeat coverage and stronger investment spreads is reshaping how investors are valuing the REIT. See our latest analysis for Omega Healthcare Investors. The upbeat earnings surprise and analyst attention have helped sustain a constructive tone around Omega Healthcare Investors, with a roughly 6.8% 1 month share price return and a 24.8% 1...

Sana Biotechnology, Inc. recently reported a quarterly loss that was narrower than expected and outlined a renewed focus on SC451 therapies and its in vivo CAR T platform, supported by tighter operational cost controls. Alongside these updates, the company’s participation in high-profile healthcare conferences hosted by Citi and Evercore signals an effort to highlight its refined pipeline priorities to the broader investment community. With these shifts in focus and communication, we’ll now...

Cloudflare (NET) is back in the spotlight after a global network outage rattled confidence in its infrastructure reliability, pulling the stock down roughly 21% over the past month and sharpening questions about long term resilience. See our latest analysis for Cloudflare. Zooming out, that outage-driven selloff sits against a powerful backdrop. Cloudflare’s share price has surged year to date with an 81.4% share price return and an 84.8% one-year total shareholder return, suggesting...

Hershey (HSY) has quietly climbed about 10% over the past month, even as its three year return still lags. That mix of recent momentum and longer term underperformance is where things get interesting. See our latest analysis for Hershey. At around $182.46, Hershey’s 1 month share price return near 10 percent has helped lift its year to date share price gain into positive territory. However, the 3 year total shareholder return remains negative, suggesting momentum may be tentatively rebuilding...

Wondering if Starbucks at around $85 a share is a bargain or a value trap? You are not alone, and this article is written exactly for investors asking that question. Despite a solid 6.8% gain over the last month, the stock is still down 7.8% year to date and about 12.1% over the past year, which hints that the market is still wrestling with what Starbucks is really worth. Recent headlines have focused on Starbucks pushing ahead with store format innovation, including smaller, drive through...

Arrowhead Pharmaceuticals (ARWR) just got a meaningful regulatory boost, with the FDA granting Breakthrough Therapy designation to its triglyceride lowering drug plozasiran. This move could streamline development timelines and sharpen investor focus. See our latest analysis for Arrowhead Pharmaceuticals. The Breakthrough Therapy nod lands on top of a powerful run, with a roughly 71% 1 month share price return and about 189% 1 year total shareholder return. This suggests momentum is still very...

Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 67% gain in the last month alone. The...